- Home
- QQQX vs SNDX Comparison
QQQX vs SNDX Comparison
Compare QQQX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- SNDX
- Stock Information
- Founded
- QQQX 2007
- SNDX 2005
- Country
- QQQX United States
- SNDX United States
- Employees
- QQQX N/A
- SNDX N/A
- Industry
- QQQX Finance Companies
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- SNDX Health Care
- Exchange
- QQQX Nasdaq
- SNDX Nasdaq
- Market Cap
- QQQX 1.2B
- SNDX 974.9M
- IPO Year
- QQQX N/A
- SNDX 2016
- Fundamental
- Price
- QQQX $22.38
- SNDX $11.54
- Analyst Decision
- QQQX
- SNDX Strong Buy
- Analyst Count
- QQQX 0
- SNDX 10
- Target Price
- QQQX N/A
- SNDX $36.20
- AVG Volume (30 Days)
- QQQX 127.6K
- SNDX 1.9M
- Earning Date
- QQQX 01-01-0001
- SNDX 05-07-2025
- Dividend Yield
- QQQX 7.03%
- SNDX N/A
- EPS Growth
- QQQX N/A
- SNDX N/A
- EPS
- QQQX N/A
- SNDX N/A
- Revenue
- QQQX N/A
- SNDX $23,680,000.00
- Revenue This Year
- QQQX N/A
- SNDX $286.51
- Revenue Next Year
- QQQX N/A
- SNDX $120.86
- P/E Ratio
- QQQX N/A
- SNDX N/A
- Revenue Growth
- QQQX N/A
- SNDX N/A
- 52 Week Low
- QQQX $20.27
- SNDX $9.66
- 52 Week High
- QQQX $25.99
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- QQQX 41.29
- SNDX 44.37
- Support Level
- QQQX $20.34
- SNDX $9.66
- Resistance Level
- QQQX $23.60
- SNDX $11.61
- Average True Range (ATR)
- QQQX 1.07
- SNDX 1.01
- MACD
- QQQX 0.08
- SNDX 0.02
- Stochastic Oscillator
- QQQX 53.12
- SNDX 56.12
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.